Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy AZN Stock  Free AZN Stock Alerts

AstraZeneca (AZN) Financials

AstraZeneca logo
$70.33 -1.76 (-2.44%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$70.11 -0.22 (-0.31%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AstraZeneca

Annual Income Statements for AstraZeneca

This table shows AstraZeneca's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 12,366 12,887 12,887 3,985 2,058 11,632 -167 9,261 17,086 18,113
Consolidated Net Income / (Loss)		 12,365 13,074 13,153 4,196 1,227 11,736 -173 9,254 17,074 18,102
Net Income / (Loss) Continuing Operations		 12,365 13,074 13,153 4,196 141 11,736 -173 9,254 17,074 18,102
Total Pre-Tax Income 		12,640 13,220 12,512 4,196 1,548 11,736 -265 9,254 17,074 18,102
Total Operating Income		 12,531 14,797 12,285 6,697 2,924 12,489 1,961 10,611 18,674 19,821
Total Gross Profit		 20,062 18,876 18,147 17,154 19,463 21,318 24,980 31,960 37,543 43,866
Total Revenue		 27,579 26,568 25,579 25,537 24,384 33,932 37,919 50,184 56,432 63,940
Operating Revenue		 27,579 26,568 25,579 25,537 - 33,932 37,919 50,184 56,432 63,940
Total Cost of Revenue		 -1,219 -2,798 -719 5,321 4,921 5,698 12,889 12,927 8,807 10,762
Operating Cost of Revenue		 -1,219 -2,798 -719 5,321 4,921 5,698 12,889 12,927 8,807 10,762
Total Operating Expenses		 16,267 14,569 14,013 13,519 17,741 15,745 23,019 26,646 28,951 33,357
Selling, General & Admin Expense		 11,112 9,413 10,233 10,077 11,682 11,462 14,608 17,301 19,622 19,897
Research & Development Expense		 5,997 5,890 5,757 5,932 6,059 5,991 9,736 9,762 10,935 13,583
Other Operating Expenses / (Income)		 -842 -734 -1,977 -2,490 - -1,708 -1,325 -417 -1,606 -123
Total Other Income / (Expense), net		 109 -1,577 227 -2,501 -1,260 -753 -2,134 -1,357 -1,600 -1,719
Other Income / (Expense), net		 108 -1,578 226 -2,509 - -753 -2,134 -1,357 -1,600 -1,719
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.00 187 266 211 -108 104 -6.00 -7.00 -12 -11
Basic Earnings per Share		 $2.23 $2.77 $2.37 $1.70 $1.03 $2.44 - $2.12 $3.84 $4.54
Weighted Average Basic Shares Outstanding		 1.26B 1.27B 1.27B 1.27B 1.30B 1.31B 1.42B 1.55B 1.55B 1.55B
Diluted Earnings per Share		 $2.23 $2.76 $2.37 $1.70 $1.03 $2.44 - $2.11 $3.81 $4.50
Weighted Average Diluted Shares Outstanding		 1.27B 1.27B 1.27B 1.27B 1.30B 1.31B 2.85B 1.56B 1.56B 1.56B
Weighted Average Basic & Diluted Shares Outstanding		 - - 1.27B 1.27B 1.30B 1.31B 1.42B 1.55B 1.55B 1.55B

Quarterly Income Statements for AstraZeneca

No quarterly income statements for AstraZeneca are available.

Annual Cash Flow Statements for AstraZeneca

This table details how cash moves in and out of AstraZeneca's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 4,280 -1,148 -1,686 1,537 547 5,208 20,121 13,786 10,520 20,354
Net Cash From Operating Activities		 5,164 4,145 3,578 7,939 2,969 6,817 11,175 15,057 15,462 18,501
Net Cash From Continuing Operating Activities		 5,164 4,588 1,536 7,939 -128 6,817 11,175 15,057 15,462 18,501
Net Income / (Loss) Continuing Operations		 0.00 3,552 2,227 0.00 1,548 0.00 0.00 0.00 0.00 0.00
Depreciation Expense		 2,852 - - - - 3,149 6,530 5,480 5,387 6,688
Non-Cash Adjustments To Reconcile Net Income		 2,312 181 926 8,476 -1,772 3,668 4,645 9,577 10,075 11,813
Net Cash From Investing Activities		 0.00 -3,969 -2,328 -626 657 0.00 776 0.00 0.00 13
Net Cash From Continuing Investing Activities		 0.00 -3,663 -1,894 -626 -98 0.00 776 0.00 0.00 13
Purchase of Investments		 - -1,098 -96 405 -1,494 - 776 0.00 - 13
Net Cash From Financing Activities		 -884 -1,324 -2,936 -4,982 1,765 -1,609 8,170 -1,271 -4,942 1,840
Net Cash From Continuing Financing Activities		 -884 -1,326 -2,916 -4,982 -737 -1,609 8,170 -1,271 -4,942 1,840
Repayment of Debt		 -884 0.00 -1,764 -1,400 -1,686 -1,609 -4,759 -1,271 -4,942 -4,652
Issuance of Debt		 - 2,491 1,988 -98 500 - 12,929 - - 6,492
Cash Interest Received		 123 - - 193 - 47 34 60 287 343

Quarterly Cash Flow Statements for AstraZeneca

No quarterly cash flow statements for AstraZeneca are available.

Annual Balance Sheets for AstraZeneca

This table presents AstraZeneca's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 60,056 62,526 63,354 60,651 61,377 66,729 105,363 96,483 101,119 104,035
Total Current Assets		 16,007 13,262 13,150 15,591 15,563 19,544 26,244 22,593 25,054 25,827
Cash & Equivalents		 6,240 5,018 3,324 4,831 5,369 7,832 6,329 6,166 5,840 5,488
Short-Term Investments		 615 911 1,258 1,107 885 302 152 326 238 220
Accounts Receivable		 6,622 4,573 5,009 5,574 5,761 7,022 9,644 10,521 12,126 12,972
Inventories, net		 2,143 2,334 3,035 3,872 3,263 4,024 9,351 4,699 5,424 5,288
Current Deferred & Refundable Income Taxes		 387 426 524 207 285 364 663 731 1,426 1,859
Plant, Property, & Equipment, net		 6,413 6,848 7,615 7,421 7,688 8,251 9,183 8,507 9,402 10,252
Plant, Property & Equipment, gross		 6,413 6,848 7,615 7,421 7,688 8,251 9,183 8,507 9,402 10,252
Total Noncurrent Assets		 37,636 42,416 42,589 37,639 38,126 17,987 27,549 65,383 66,663 67,956
Long-Term Investments		 543 826 1,036 922 1,459 1,147 1,237 1,142 1,677 1,900
Noncurrent Note & Lease Receivables		 907 901 847 515 740 720 895 835 803 930
Goodwill		 11,800 11,658 11,825 11,707 11,668 11,845 19,997 19,820 20,048 21,025
Intangible Assets		 22,646 27,586 26,188 21,959 20,833 - - 39,307 38,089 37,177
Noncurrent Deferred & Refundable Income Taxes		 1,294 1,102 2,189 2,379 2,718 3,438 4,330 3,263 4,718 5,347
Other Noncurrent Operating Assets		 446 343 504 157 708 837 1,090 1,016 1,328 1,577
Total Liabilities & Shareholders' Equity		 58,621 61,080 61,926 59,211 59,331 65,306 103,919 95,015 99,655 102,624
Total Liabilities		 41,547 45,857 46,712 46,607 46,781 51,091 66,076 59,425 61,953 63,164
Total Current Liabilities		 14,869 15,256 16,383 16,292 18,117 20,307 22,594 26,293 30,542 27,866
Short-Term Debt		 916 2,307 2,247 1,754 1,822 2,194 1,660 5,314 5,129 2,337
Accounts Payable		 11,663 10,486 11,641 12,841 13,987 15,785 18,938 19,040 22,374 22,465
Current Deferred & Payable Income Tax Liabilities		 1,483 1,380 - 1,164 1,361 1,127 916 896 1,584 1,406
Other Current Liabilities		 807 1,083 1,145 533 947 1,201 1,080 1,043 1,455 1,658
Total Noncurrent Liabilities		 26,678 30,601 30,329 30,315 28,664 30,784 43,482 33,132 31,411 35,298
Long-Term Debt		 14,137 14,501 15,560 17,359 15,730 17,507 28,134 22,965 22,365 26,506
Capital Lease Obligations		 - - 0.00 0.00 487 489 754 725 857 1,113
Noncurrent Deferred & Payable Income Tax Liabilities		 2,665 3,956 3,995 3,286 2,490 2,918 6,206 2,944 2,844 3,543
Noncurrent Employee Benefit Liabilities		 1,974 2,186 2,583 2,511 2,807 3,202 2,454 1,168 1,520 1,330
Other Noncurrent Operating Liabilities		 7,902 9,958 8,191 7,159 7,150 6,668 5,934 5,330 3,825 2,806
Total Equity & Noncontrolling Interests		 17,074 15,223 15,214 12,604 14,596 14,215 37,843 35,590 37,702 39,460
Total Preferred & Common Equity		 36,999 31,523 31,602 26,512 11,081 31,260 78,555 74,095 78,309 81,657
Preferred Stock		 4,304 4,351 4,393 4,427 - 7,971 35,126 35,155 35,188 35,226
Total Common Equity		 12,751 9,057 9,139 6,601 13,127 6,228 2,698 414 2,491 4,149
Common Stock		 316 316 317 317 328 328 387 387 388 388
Retained Earnings		 11,834 8,140 8,221 5,683 2,812 5,299 1,710 -574 1,502 3,160
Other Equity Adjustments		 601 601 601 601 7,941 601 601 601 601 601
Noncontrolling Interest		 19 1,815 1,682 1,576 1,469 16 19 21 23 85

Quarterly Balance Sheets for AstraZeneca

This table presents AstraZeneca's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q4 2023 Q4 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 96,483 101,119 104,035
Total Current Assets		 22,593 25,054 25,827
Cash & Equivalents		 6,166 5,840 5,488
Short-Term Investments		 326 238 220
Accounts Receivable		 10,521 12,126 12,972
Inventories, net		 4,699 5,424 5,288
Current Deferred & Refundable Income Taxes		 731 1,426 1,859
Plant, Property, & Equipment, net		 8,507 9,402 10,252
Plant, Property & Equipment, gross		 8,507 9,402 10,252
Total Noncurrent Assets		 65,383 66,663 67,956
Long-Term Investments		 1,142 1,677 1,900
Noncurrent Note & Lease Receivables		 835 803 930
Goodwill		 19,820 20,048 21,025
Intangible Assets		 39,307 38,089 37,177
Noncurrent Deferred & Refundable Income Taxes		 3,263 4,718 5,347
Other Noncurrent Operating Assets		 1,016 1,328 1,577
Total Liabilities & Shareholders' Equity		 95,015 99,655 102,624
Total Liabilities		 59,425 61,953 63,164
Total Current Liabilities		 26,293 30,542 27,866
Short-Term Debt		 5,314 5,129 2,337
Accounts Payable		 19,040 22,374 22,465
Current Deferred & Payable Income Tax Liabilities		 896 1,584 1,406
Other Current Liabilities		 1,043 1,455 1,658
Total Noncurrent Liabilities		 33,132 31,411 35,298
Long-Term Debt		 22,965 22,365 26,506
Capital Lease Obligations		 725 857 1,113
Noncurrent Deferred & Payable Income Tax Liabilities		 2,944 2,844 3,543
Noncurrent Employee Benefit Liabilities		 1,168 1,520 1,330
Other Noncurrent Operating Liabilities		 5,330 3,825 2,806
Total Equity & Noncontrolling Interests		 35,590 37,702 39,460
Total Preferred & Common Equity		 74,095 78,309 81,657
Preferred Stock		 35,155 35,188 35,226
Total Common Equity		 414 2,491 4,149
Common Stock		 387 388 388
Retained Earnings		 -574 1,502 3,160
Other Equity Adjustments		 601 601 601
Noncontrolling Interest		 21 23 85

Annual Metrics and Ratios for AstraZeneca

This table displays calculated financial ratios and metrics derived from AstraZeneca's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -3.67% -3.72% -0.16% -4.52% 39.16% 11.75% 32.35% 12.45% 13.30%
EBITDA Growth		 0.00% -14.67% -5.36% -66.53% -30.18% 409.06% -57.29% 131.78% 52.44% 10.37%
EBIT Growth		 0.00% 4.59% -5.36% -66.53% -30.18% 301.37% -101.47% 5,449.13% 84.50% 6.02%
NOPAT Growth		 0.00% 19.07% -11.75% -48.14% -65.39% 438.86% -89.01% 673.00% 75.99% 6.14%
Net Income Growth		 0.00% 5.73% 0.60% -68.10% -70.76% 856.48% -101.47% 5,449.13% 84.50% 6.02%
EPS Growth		 0.00% 23.77% -14.13% -28.27% -39.41% 136.89% 0.00% 0.00% 80.57% 18.11%
Operating Cash Flow Growth		 0.00% -19.73% -13.68% 121.88% -62.60% 129.61% 63.93% 34.74% 2.69% 19.65%
Free Cash Flow Firm Growth		 0.00% 0.00% -23.23% -14.57% -60.00% 761.46% -139.77% -121.64% 161.30% -4.81%
Invested Capital Growth		 0.00% 2.13% 7.89% -8.79% -5.23% -77.53% 250.45% 196.96% 2.55% 5.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 72.74% 71.05% 70.94% 67.17% 79.82% 62.83% 65.88% 63.69% 66.53% 68.60%
EBITDA Margin		 56.17% 49.76% 48.91% 16.40% 11.99% 43.87% 16.76% 29.36% 39.80% 38.77%
Operating Margin		 45.44% 55.69% 48.03% 26.22% 11.99% 36.81% 5.17% 21.14% 33.09% 31.00%
EBIT Margin		 45.83% 49.76% 48.91% 16.40% 11.99% 34.59% -0.46% 18.44% 30.26% 28.31%
Profit (Net Income) Margin		 44.83% 49.21% 51.42% 16.43% 5.03% 34.59% -0.46% 18.44% 30.26% 28.31%
Tax Burden Percent		 97.82% 98.90% 105.12% 100.00% 79.26% 100.00% 65.28% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.01% 100.01% 100.01% 100.19% 52.94% 100.00% 153.18% 100.00% 100.00% 100.00%
Effective Tax Rate		 1.92% 1.10% -5.12% 0.00% 20.74% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 46.97% 55.34% 46.49% 24.30% 9.05% 81.84% 10.88% 27.24% 31.64% 32.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 47.80% 40.19% 48.39% 5.98% -0.03% -6.18% 22.40% -33.47% 24.49% 24.73%
Return on Net Nonoperating Assets (RNNOA)		 25.45% 25.62% 39.93% 5.87% -0.03% -0.37% -11.55% -2.04% 14.95% 14.69%
Return on Equity (ROE)		 72.42% 80.96% 86.43% 30.17% 9.02% 81.47% -0.66% 25.20% 46.59% 46.92%
Cash Return on Invested Capital (CROIC)		 0.00% 53.23% 38.90% 33.49% 14.42% 208.45% -100.32% -71.99% 29.13% 26.61%
Operating Return on Assets (OROA)		 21.05% 21.57% 19.88% 6.75% 4.79% 18.32% -0.20% 9.17% 17.28% 17.65%
Return on Assets (ROA)		 20.59% 21.33% 20.90% 6.77% 2.01% 18.32% -0.20% 9.17% 17.28% 17.65%
Return on Common Equity (ROCE)		 54.08% 54.67% 51.67% 17.07% 6.54% 54.73% -0.11% 1.07% 1.85% 4.04%
Return on Equity Simple (ROE_SIMPLE)		 33.42% 41.47% 41.62% 15.83% 11.07% 37.54% -0.22% 12.49% 21.80% 22.17%
Net Operating Profit after Tax (NOPAT)		 12,290 14,634 12,914 6,697 2,318 12,489 1,373 10,611 18,674 19,821
NOPAT Margin		 44.56% 55.08% 50.49% 26.22% 9.50% 36.81% 3.62% 21.14% 33.09% 31.00%
Net Nonoperating Expense Percent (NNEP)		 -0.82% 15.15% -1.90% 18.32% 9.08% 88.02% -11.52% 60.72% 7.15% 7.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 16.43% 28.27% 28.55%
Cost of Revenue to Revenue		 -4.42% -10.53% -2.81% 20.84% 20.18% 16.79% 33.99% 25.76% 15.61% 16.83%
SG&A Expenses to Revenue		 40.29% 35.43% 40.01% 39.46% 47.91% 33.78% 38.52% 34.48% 34.77% 31.12%
R&D to Revenue		 21.74% 22.17% 22.51% 23.23% 24.85% 17.66% 25.68% 19.45% 19.38% 21.24%
Operating Expenses to Revenue		 58.98% 54.84% 54.78% 52.94% 72.76% 46.40% 60.71% 53.10% 51.30% 52.17%
Earnings before Interest and Taxes (EBIT)		 12,639 13,219 12,511 4,188 2,924 11,736 -173 9,254 17,074 18,102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 15,491 13,219 12,511 4,188 2,924 14,885 6,357 14,734 22,461 24,790
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 6.15 4.20 9.45 26.14 0.00 40.40 24.48
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 1.59 2.26 1.74 1.86 0.00 1.78 1.59
Price to Earnings (P/E)		 0.00 0.00 0.00 10.19 26.79 5.06 0.00 0.00 5.89 5.61
Dividend Yield		 5.58% 6.62% 4.97% 4.37% 3.22% 3.12% 2.61% 2.27% 2.23% 3.77%
Earnings Yield		 0.00% 0.00% 0.00% 9.81% 3.73% 19.76% 0.00% 0.00% 16.98% 17.83%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.24 2.69 13.89 6.55 0.00 2.62 2.52
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.30 2.74 2.29 3.39 0.00 2.77 2.49
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 14.05 22.89 5.22 20.21 0.00 6.96 6.42
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 14.05 22.89 6.63 0.00 0.00 9.16 8.80
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 8.79 28.88 6.23 93.60 0.00 8.38 8.03
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 7.41 22.54 11.41 11.50 0.00 10.12 8.61
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 6.38 18.12 2.44 0.00 0.00 9.10 9.73
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.88 1.10 1.17 1.52 1.24 1.42 0.81 0.81 0.75 0.76
Long-Term Debt to Equity		 0.83 0.95 1.02 1.38 1.11 1.27 0.76 0.67 0.62 0.70
Financial Leverage		 0.53 0.64 0.83 0.98 0.88 0.06 -0.52 0.06 0.61 0.59
Leverage Ratio		 3.52 3.80 4.14 4.46 4.49 4.45 3.31 2.75 2.70 2.66
Compound Leverage Factor		 3.52 3.80 4.14 4.47 2.38 4.45 5.06 2.75 2.70 2.66
Debt to Total Capital		 46.85% 52.47% 53.93% 60.26% 55.28% 58.68% 44.67% 44.90% 42.92% 43.15%
Short-Term Debt to Total Capital		 2.85% 7.20% 6.80% 5.53% 5.58% 6.38% 2.43% 8.23% 7.77% 3.37%
Long-Term Debt to Total Capital		 44.00% 45.27% 47.12% 54.73% 49.69% 52.31% 42.24% 36.68% 35.16% 39.79%
Preferred Equity to Total Capital		 13.40% 13.58% 13.30% 13.96% 0.00% 23.17% 51.36% 54.42% 53.27% 50.75%
Noncontrolling Interests to Total Capital		 0.06% 5.67% 5.09% 4.97% 4.50% 0.05% 0.03% 0.03% 0.03% 0.12%
Common Equity to Total Capital		 39.69% 28.28% 27.68% 20.81% 40.22% 18.10% 3.95% 0.64% 3.77% 5.98%
Debt to EBITDA		 0.97 1.27 1.42 4.56 6.17 1.36 4.81 1.97 1.26 1.21
Net Debt to EBITDA		 0.49 0.76 0.97 2.93 3.53 0.73 3.59 1.45 0.92 0.90
Long-Term Debt to EBITDA		 0.91 1.10 1.24 4.14 5.55 1.21 4.54 1.61 1.03 1.11
Debt to NOPAT		 1.22 1.15 1.38 2.85 7.78 1.62 22.25 2.73 1.52 1.51
Net Debt to NOPAT		 0.62 0.69 0.94 1.83 4.46 0.87 16.63 2.01 1.10 1.13
Long-Term Debt to NOPAT		 1.15 0.99 1.20 2.59 7.00 1.44 21.04 2.23 1.24 1.39
Altman Z-Score		 0.00 0.00 0.00 1.29 1.28 1.88 1.06 0.00 2.05 2.17
Noncontrolling Interest Sharing Ratio		 25.32% 32.48% 40.22% 43.42% 27.47% 32.82% 82.85% 95.76% 96.04% 91.39%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.08 0.87 0.80 0.96 0.86 0.96 1.16 0.86 0.82 0.93
Quick Ratio		 0.91 0.69 0.59 0.71 0.66 0.75 0.71 0.65 0.60 0.67
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 14,076 10,805 9,231 3,693 31,811 -12,652 -28,042 17,190 16,364
Operating Cash Flow to CapEx		 0.00% 0.00% 2,222.36% 770.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 2.58 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 2.07 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 2.87 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.46 0.43 0.41 0.41 0.40 0.53 0.44 0.50 0.57 0.62
Accounts Receivable Turnover		 4.16 4.75 5.34 4.83 4.30 5.31 4.55 4.98 4.98 5.10
Inventory Turnover		 0.00 0.00 0.00 1.54 1.38 1.56 1.93 1.84 1.74 2.01
Fixed Asset Turnover		 4.30 4.01 3.54 3.40 3.23 4.26 4.35 5.67 6.30 6.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.43 0.37 0.38 0.74 0.68 0.43 0.48
Days Sales Outstanding (DSO)		 87.64 76.90 68.37 75.63 84.84 68.75 80.21 73.33 73.24 71.64
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 236.90 264.61 233.39 189.38 198.35 209.77 181.65
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 839.69 994.94 953.56 491.66 536.16 858.19 760.37
Cash Conversion Cycle (CCC)		 87.64 76.90 68.37 -527.16 -645.50 -651.42 -222.06 -264.48 -575.18 -507.08
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 26,164 26,722 28,831 26,297 24,922 5,600 19,625 58,278 59,762 63,219
Invested Capital Turnover		 1.05 1.00 0.92 0.93 0.95 2.22 3.01 1.29 0.96 1.04
Increase / (Decrease) in Invested Capital		 0.00 558 2,109 -2,534 -1,375 -19,322 14,025 38,653 1,484 3,457
Enterprise Value (EV)		 0.00 0.00 0.00 58,861 66,923 77,768 128,490 0.00 156,436 159,229
Market Capitalization		 0.00 0.00 0.00 40,605 55,128 58,872 70,515 0.00 100,629 101,570
Book Value per Share		 $10.09 $7.16 $7.22 $5.21 $10.36 $4.75 $2.06 $0.27 $1.61 $2.68
Tangible Book Value per Share		 ($17.16) ($23.86) ($22.81) ($21.37) ($15.29) ($4.28) ($13.18) ($37.93) ($35.90) ($34.87)
Total Capital		 32,127 32,031 33,021 31,717 32,635 34,405 68,391 64,594 66,053 69,416
Total Debt		 15,053 16,808 17,807 19,113 18,039 20,190 30,548 29,004 28,351 29,956
Total Long-Term Debt		 14,137 14,501 15,560 17,359 16,217 17,996 28,888 23,690 23,222 27,619
Net Debt		 7,655 10,053 12,189 12,253 10,326 10,909 22,830 21,370 20,596 22,348
Capital Expenditures (CapEx)		 0.00 -63 161 1,031 -1,134 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4,801 -5,616 -5,568 -4,885 -6,986 -6,703 -1,171 -4,878 -6,437 -5,410
Debt-free Net Working Capital (DFNWC)		 2,054 313 -986 1,053 -732 1,431 5,310 1,614 -359 298
Net Working Capital (NWC)		 1,138 -1,994 -3,233 -701 -2,554 -763 3,650 -3,700 -5,488 -2,039
Net Nonoperating Expense (NNE)		 -75 1,560 -239 2,501 1,091 753 1,546 1,357 1,600 1,719
Net Nonoperating Obligations (NNO)		 9,090 11,499 13,617 13,693 10,326 -8,615 -18,218 22,688 22,060 23,759
Total Depreciation and Amortization (D&A)		 2,852 0.00 0.00 0.00 0.00 3,149 6,530 5,480 5,387 6,688
Debt-free, Cash-free Net Working Capital to Revenue		 -17.41% -21.14% -21.77% -19.13% -28.65% -19.75% -3.09% -9.72% -11.41% -8.46%
Debt-free Net Working Capital to Revenue		 7.45% 1.18% -3.85% 4.12% -3.00% 4.22% 14.00% 3.22% -0.64% 0.47%
Net Working Capital to Revenue		 4.13% -7.51% -12.64% -2.75% -10.47% -2.25% 9.63% -7.37% -9.73% -3.19%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $2.37 $1.70 $1.03 $2.44 $0.00 $2.12 $3.84 $4.54
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.27B 1.27B 1.30B 1.31B 0.00 1.55B 1.55B 1.55B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $2.37 $1.70 $1.03 $2.44 $0.00 $2.11 $3.81 $4.50
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.27B 1.27B 1.30B 1.31B 0.00 1.56B 1.56B 1.56B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.27B 1.27B 1.31B 1.31B 0.00 1.55B 1.55B 1.55B
Normalized Net Operating Profit after Tax (NOPAT)		 12,290 14,634 8,600 4,688 2,318 8,742 1,373 7,428 13,072 13,875
Normalized NOPAT Margin		 44.56% 55.08% 33.62% 18.36% 9.50% 25.76% 3.62% 14.80% 23.16% 21.70%
Pre Tax Income Margin		 45.83% 49.76% 48.92% 16.43% 6.35% 34.59% -0.70% 18.44% 30.26% 28.31%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 2.04 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 1.62 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 2.83 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 2.41 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 27.24% 26.75% 83.03% 292.75% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 27.24% 26.75% 83.03% 292.75% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for AstraZeneca

No quarterly metrics and ratios for AstraZeneca are available.

Frequently Asked Questions About AstraZeneca's Financials

When does AstraZeneca's financial year end?

According to the most recent income statement we have on file, AstraZeneca's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AstraZeneca's net income changed over the last 9 years?

AstraZeneca's net income appears to be on an upward trend, with a most recent value of $18.10 billion in 2024, rising from $12.37 billion in 2015. The previous period was $17.07 billion in 2023. See where experts think AstraZeneca is headed by visiting AstraZeneca's forecast page.

What is AstraZeneca's operating income?
AstraZeneca's total operating income in 2024 was $19.82 billion, based on the following breakdown:
  • Total Gross Profit: $43.87 billion
  • Total Operating Expenses: $33.36 billion
How has AstraZeneca revenue changed over the last 9 years?

Over the last 9 years, AstraZeneca's total revenue changed from $27.58 billion in 2015 to $63.94 billion in 2024, a change of 131.8%.

How much debt does AstraZeneca have?

AstraZeneca's total liabilities were at $63.16 billion at the end of 2024, a 2.0% increase from 2023, and a 52.0% increase since 2015.

How much cash does AstraZeneca have?

In the past 9 years, AstraZeneca's cash and equivalents has ranged from $3.32 billion in 2017 to $7.83 billion in 2020, and is currently $5.49 billion as of their latest financial filing in 2024.

How has AstraZeneca's book value per share changed over the last 9 years?

Over the last 9 years, AstraZeneca's book value per share changed from 10.09 in 2015 to 2.68 in 2024, a change of -73.5%.


Related Companies

This page (NASDAQ:AZN) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored